In addition, we have a phase 1/2a clinical trial delivering CNS10-NPC to patients with retinitis pigmentosa (NCT04284293)24 and are performing IND-enabling studies to deliver CNS10-NPC-GDNF to patients with Parkinson’s disease. Here, GDNF is linked to retinitis pigmentosa.